Clinical Outcomes and Co-Occurring Mutations in Patients with RUNX1-Mutated Acute Myeloid Leukemia

(1) Runt-related transcription factor 1 (RUNX1) mutations in acute myeloid leukemia (AML) are often associated with worse prognosis. We assessed co-occurring mutations, response to therapy, and clinical outcomes in patients with and without mutant RUNX1 (mRUNX1); (2) We analyzed 328 AML patients, including 177 patients younger than 65 years who received intensive chemotherapy and 151 patients >65 years who received hypomethylating agents. RUNX1 and co-existing mutations were identified using next-generation sequencing; (3) RUNX1 mutations were identified in 5.1% of younger patients and 15.9% of older patients, and were significantly associated with increasing age (p = 0.01) as well as intermediate-risk cytogenetics including normal karyotype (p = 0.02) in the elderly cohort, and with lower lactate dehydrogenase (LDH; p = 0.02) and higher platelet count (p = 0.012) overall. Identified co-occurring mutations were primarily ASXL1 mutations in older patients and RAS mutations in younger patients; FLT3-ITD and IDH1/2 co-mutations were also frequent. Younger mRUNX1 AML patients treated with intensive chemotherapy experienced inferior treatment outcomes. In older patients with AML treated with hypomethylating agent (HMA) therapy, response and survival was independent of RUNX1 status. Older mRUNX1 patients with prior myelodysplastic syndrome or myeloproliferative neoplasms (MDS/MPN) had particularly dismal outcome. Future studies should focus on the prognostic implications of RUNX1 mutations relative to other co-occurring mutations, and the potential role of hypomethylating agents for this molecularly-defined group.

[1]  E. F. de Oliveira,et al.  Standardization of DNA extraction from sand flies: Application to genotyping by next generation sequencing. , 2017, Experimental parasitology.

[2]  W. Zhang,et al.  Impaired DNA double-strand break repair contributes to the age-associated rise of genomic instability in humans , 2016, Cell Death and Differentiation.

[3]  Jennifer D. Churchill,et al.  Analysis of Short Tandem Repeat and Single Nucleotide Polymorphism Loci From Single-Source Samples Using a Custom HaloPlex Target Enrichment System Panel , 2016, The American journal of forensic medicine and pathology.

[4]  H. Kestler,et al.  RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features , 2016, Leukemia.

[5]  D. Johnston,et al.  Clinical Impact of Additional Cytogenetic Aberrations, cKIT and RAS Mutations, and Treatment Elements in Pediatric t(8;21)-AML: Results From an International Retrospective Study by the International Berlin-Frankfurt-Münster Study Group. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  H. Kantarjian,et al.  Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib. , 2015, Blood.

[7]  S. Gabriel,et al.  Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. , 2014, The New England journal of medicine.

[8]  D. Neuberg,et al.  TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. , 2014, Blood.

[9]  Joshua F. McMichael,et al.  Age-related cancer mutations associated with clonal hematopoietic expansion , 2014, Nature Medicine.

[10]  D. Liang,et al.  Gene Mutation Patterns in Patients with Minimally Differentiated Acute Myeloid Leukemia☆ , 2014, Neoplasia.

[11]  Craig L. Peterson,et al.  Chromatin and the genome integrity network , 2012, Nature Reviews Genetics.

[12]  Wolfgang Hiddemann,et al.  RUNX1 mutations in cytogenetically normal acute myeloid leukemia are associated with a poor prognosis and up-regulation of lymphoid genes , 2012, Haematologica.

[13]  H. Kantarjian,et al.  Clinical impact of change of FLT3 mutation status in acute myeloid leukemia patients , 2012, Modern Pathology.

[14]  Guido Marcucci,et al.  RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Shinichirou Takahashi.  Current findings for recurring mutations in acute myeloid leukemia , 2011, Journal of hematology & oncology.

[16]  R. Hills,et al.  The prognostic significance of IDH2 mutations in AML depends on the location of the mutation. , 2011, Blood.

[17]  Verena I Gaidzik,et al.  RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  T. Haferlach,et al.  RUNX1 mutations are frequent in de novo AML with noncomplex karyotype and confer an unfavorable prognosis. , 2011, Blood.

[19]  B. Ko,et al.  Distinct clinical and biological features of de novo acute myeloid leukemia with additional sex comb-like 1 (ASXL1) mutations. , 2010, Blood.

[20]  Chieh-Yu Liu,et al.  AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations. , 2009, Blood.

[21]  Steven J. M. Jones,et al.  Circos: an information aesthetic for comparative genomics. , 2009, Genome research.

[22]  M. Hoshi,et al.  High frequency of AML1/RUNX1 point mutations in radiation-associated myelodysplastic syndrome around Semipalatinsk nuclear test site. , 2008, Journal of radiation research.

[23]  B. Ko,et al.  RUNX1 gene mutation in primary myelodysplastic syndrome – the mutation can be detected early at diagnosis or acquired during disease progression and is associated with poor outcome , 2007, British journal of haematology.

[24]  Motomi Osato.  Point mutations in the RUNX1/AML1 gene: another actor in RUNX leukemia , 2004, Oncogene.

[25]  T. Kyo,et al.  High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia. , 2004, Blood.

[26]  C. Bloomfield,et al.  Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  T. Naoe,et al.  Dual mutations in the AML1 and FLT3 genes are associated with leukemogenesis in acute myeloblastic leukemia of the M0 subtype , 2003, Leukemia.

[28]  T. Inaba,et al.  Implications of somatic mutations in the AML1 gene in radiation-associated and therapy-related myelodysplastic syndrome/acute myeloid leukemia. , 2003, Blood.

[29]  J. Griffin,et al.  The roles of FLT3 in hematopoiesis and leukemia. , 2002, Blood.

[30]  R. Gray,et al.  Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council's 10th AML trial (MRC AML10). Adult and Childhood Leukaemia Working Parties of the Medical Research Council. , 1997, Blood.

[31]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[32]  D. Niederwieser,et al.  The role of hypomethylating agents in the treatment of elderly patients with AML. , 2014, Journal of geriatric oncology.

[33]  N. Schmitz,et al.  ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome , 2013, Leukemia.

[34]  E. Hoster,et al.  Age-dependent frequencies of NPM1 mutations and FLT3-ITD in patients with normal karyotype AML (NK-AML) , 2011, Annals of Hematology.